Jacob B. Geri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacob B. Geri has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Colin S. Burdette
Tri-Institutional PhD Program in Chemical Biology (TPCB), New York, NY, USA
26 shared publications - Ahmet Dogan
Memorial Sloan Kettering Cancer Center, New York, NY
25 shared publications - Alireza Karbalayghareh
Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, USA
25 shared publications - Amos Fong
British Columbia Cancer 6 Vancouver, British Columbia
25 shared publications - Amy Chadburn
Weill Cornell Medicine 13 New York, NY
25 shared publications - Ari M. Melnick
Cornell University
25 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Springer Nature in Nature Communications
Spatial protein interactomics in solid primary human tissue
- 3 November 2026
- Published by Springer Nature in Nature Communications
Open AccessSpatial protein interactomics in solid primary human tissue
- 30 October 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
NAD+ replenishment reduces cardiomyocyte senescence and improves diastolic function in the aged male heart
Aims: Cardiomyocyte senescence is a hallmark of cardiac ageing and closely associated with diastolic dysfunction and heart failure in older adults. Strategies to effectively delay or reverse cardiomyocyte senescence in the aged heart remain limited. We investigated whether NAD+ replenishment regulates cardiomyocyte senescence and cardiac function in ageing. Methods and results: Ventricular NAD+ metabolism, senescence markers, and cardiac function were assessed in young and aged mice of both sexes. Aged male mice exhibited reduced cardiac NAD+ levels due to impaired biosynthesis, limited mitochondrial mobilization, and increased consumption, leading to suppressed SIRT1 and SIRT6 activity and accumulation of senescent cardiomyocytes. These changes were accompanied by diastolic dysfunction, myocardial hypertrophy, and fibrosis. In cultured cardiomyocytes, NAD+ depletion induced cellular senescence, which was reversed by supplementation with the NAD+ precursors nicotinamide riboside (NR) and dihydronicotinamide riboside (NRH). In aged male mice, two months of NR or NRH treatment suppressed senescence markers, improved diastolic function, and reduced hypertrophy and fibrosis. Mechanistically, both NR and NRH activated SIRT1 and suppressed cell cycle arrest markers. NRH induced more robust SIRT1 activation, which deacetylated SIRT6, promoting its binding to histones and enhancing DNA damage repair. In contrast, aged female mice exhibited diastolic dysfunction without significant decline in cardiac NAD+ levels and did not respond to NR or NRH treatment. Conclusion: NAD+ is a critical regulator of cardiomyocyte senescence in ageing male hearts. NAD+ replenishment, particularly with NRH, reverses senescence-associated cardiac dysfunction through coordinated activation of SIRT1 and SIRT6. The sex-specific differences observed highlight distinct mechanisms underlying cardiac ageing and emphasize the importance of considering biological sex in the development of NAD+-based therapeutic strategies.
- 30 October 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
NAD+ replenishment reduces cardiomyocyte senescence and improves diastolic function in the aged male heart
Aims: Cardiomyocyte senescence is a hallmark of cardiac ageing and closely associated with diastolic dysfunction and heart failure in older adults. Strategies to effectively delay or reverse cardiomyocyte senescence in the aged heart remain limited. We investigated whether NAD+ replenishment regulates cardiomyocyte senescence and cardiac function in ageing. Methods and results: Ventricular NAD+ metabolism, senescence markers, and cardiac function were assessed in young and aged mice of both sexes. Aged male mice exhibited reduced cardiac NAD+ levels due to impaired biosynthesis, limited mitochondrial mobilization, and increased consumption, leading to suppressed SIRT1 and SIRT6 activity and accumulation of senescent cardiomyocytes. These changes were accompanied by diastolic dysfunction, myocardial hypertrophy, and fibrosis. In cultured cardiomyocytes, NAD+ depletion induced cellular senescence, which was reversed by supplementation with the NAD+ precursors nicotinamide riboside (NR) and dihydronicotinamide riboside (NRH). In aged male mice, two months of NR or NRH treatment suppressed senescence markers, improved diastolic function, and reduced hypertrophy and fibrosis. Mechanistically, both NR and NRH activated SIRT1 and suppressed cell cycle arrest markers. NRH induced more robust SIRT1 activation, which deacetylated SIRT6, promoting its binding to histones and enhancing DNA damage repair. In contrast, aged female mice exhibited diastolic dysfunction without significant decline in cardiac NAD+ levels and did not respond to NR or NRH treatment. Conclusion: NAD+ is a critical regulator of cardiomyocyte senescence in ageing male hearts. NAD+ replenishment, particularly with NRH, reverses senescence-associated cardiac dysfunction through coordinated activation of SIRT1 and SIRT6. The sex-specific differences observed highlight distinct mechanisms underlying cardiac ageing and emphasize the importance of considering biological sex in the development of NAD+-based therapeutic strategies.
- 8 September 2026
- Published by Springer Nature in Nature Chemical Biology
- p. 1-2
Macrophages are what they eat
- 8 September 2026
- Published by Springer Nature in Nature Chemical Biology
- p. 1-2
Macrophages are what they eat
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations induce formation of a non-canonical AiBC with MZB features.
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations induce formation of a non-canonical AiBC with MZB features.
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations lead to increased fitness of female AiBC.
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations lead to increased fitness of female AiBC.
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Differentially Expressed Genes per cluster from multiome analysis
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Differentially Expressed Genes per cluster from multiome analysis
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations drive an increase in AiBCs
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations drive an increase in AiBCs
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
AIBC Signatures used in Fig. 6 H, K and L as well as S6K
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
AIBC Signatures used in Fig. 6 H, K and L as well as S6K
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Gene Overlap used in Fig. 6L and S6K
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Gene Overlap used in Fig. 6L and S6K
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SpenLOF and Notch2GOF mutations skew mature B cells towards the MZB compartment
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SpenLOF and Notch2GOF mutations skew mature B cells towards the MZB compartment